In this video, Carolyn K. Pan, MD, a clinical professor of ophthalmology at Stanford University, discussed highlights in wet ...
Pregnancy, menopause and hormone therapy may all impact a woman’s lipoprotein(a) level, challenging the mantra of the once-in ...
Results presented at IDWeek showed prolonged antibiotic therapy beyond 12 weeks may not improve outcomes for early ...
As physicians across specialties encounter increasing patient interest in GLP-1 receptor agonists, it is important for them ...
An AI model significantly improved recurrence risk stratification vs. recurrence score among patients with hormone ...
A pharmacy-based intervention may help increase SGLT2 inhibitor use for patients with type 2 diabetes and chronic kidney ...
A greater proportion of women vs. men with COPD or bronchiectasis had their first health care visit within 6 months of ...
Individuals with gout are more likely than those without the disease to receive chronic opioid therapy, independent of other ...
In this video, Matthew S. Davids, MD, spoke about the BRUIN-314 trial, one of the first head-to-head studies to compare pirtobrutinib, a noncovalent Bruton tyrosine kinase inhibitor, with ibrutinib, a ...
Combining elacestrant with targeted agents produced “clinically meaningful” outcomes for patients with locally advanced or metastatic ER-positive/HER2-negative breast cancer who have received at least ...
Milestone Pharmaceuticals announced the FDA approval of prescription etripamil nasal spray for the treatment of acute ...
Individuals with focal onset epilepsy treated with azetukalner experienced sustained monthly seizure reduction and evidence of seizure freedom up to 48 months, according to data presented at the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback